About: A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
Creator	Byrne, Hannah O'kennedy, Richard Conroy, Paul Whisstock, James
Source	Elsevier; Medline; PMC
abstract	Artificial manipulation of antibody genes has facilitated the production of several unique recombinant antibody formats, which have highly important therapeutic and biotechnological applications. Although bispecific antibodies (bsAbs) are not new, they are coming to the forefront as our knowledge of the potential efficacy of antibody-based therapeutics expands. The next generation of bsAbs is developing due to significant improvements in recombinant antibody technologies. This review focuses on recent advances with a particular focus on improvements in format and design that are contributing to the resurgence of bsAbs, and in particular, on innovative structures applicable to next generation point-of-care (POC) devices with applicability to low resource environments.
has issue date	2013-11-30(xsd:dateTime)
bibo:doi	10.1016/j.tibtech.2013.08.007
bibo:pmid	24094861
has license	els-covid
sha1sum (hex)	8b6e02af26f8496d544e7196359aebe8c0cb14f2
schema:url	https://doi.org/10.1016/j.tibtech.2013.08.007
resource representing a document's title	A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications
has PubMed Central identifier	PMC7114091
has PubMed identifier	24094861
schema:publication	Trends in Biotechnology
resource representing a document's body	covid:8b6e02af26f8496d544e7196359aebe8c0cb14f2#body_text
is schema:about of	named entity 'THERAPEUTIC' named entity 'APPLICATIONS' named entity 'DIAGNOSTIC' named entity 'SPECIFICITIES' named entity 'BISPECIFIC ANTIBODIES' named entity 'HAMA' named entity 'sample matrix' named entity 'effector cells' named entity 'SARS' named entity 'hepatocyte growth factor receptor' named entity 'B. pertussis' named entity 'long-lasting' named entity 'antibody' named entity 'catumaxomab' named entity 'polyclonal' named entity 'B. pertussis' named entity 'outer membrane' named entity 'CD19' named entity 'light chains' named entity 'cytotoxicity' named entity 'CD4 +' named entity 'blood samples' named entity 'light chain' named entity 'CD19' named entity 'HBsAg' named entity 'erythrocyte' named entity 'preclinical' named entity 'carcinoembryonic antigen' named entity 'KLH' named entity 'Rhodamine' named entity 'antibody' named entity 'lysis' named entity 'mAb' named entity 'microbial culture' named entity 'sensitivity and specificity' named entity 'tetravalent' named entity 'CD16' named entity 'mAbs' named entity 'agglutination' named entity 'Fc-receptor' named entity 'virus' named entity 'sensitivity and specificity' named entity 'hemorrhagic colitis' named entity 'bispecific antibody' named entity 'therapeutic resistance' named entity 'antigen' named entity 'murine' named entity 'expression levels' named entity 'clinical trials' named entity 'fluorescence quenching' named entity 'allergic' named entity 'mAbs' named entity 'WHO' named entity 'LPS' named entity 'MHC' named entity 'Single domain' named entity 'chelate' named entity 'combination therapy' named entity 'mAb' named entity 'cell lysis' named entity 'Mycobacterium tuberculosis' named entity 'antigen' named entity 'binding sites' named entity 'whooping cough' named entity 'hemocyanin' named entity 'nasopharyngeal' named entity 'molecular biological' named entity 'crosslinking' named entity 'antigen' named entity 'catumaxomab' named entity 'wound infection' named entity 'effector cells' named entity 'Recombinant' named entity 'homodimer' named entity 'vaccine' named entity 'BiTE' named entity 'infectious disease' named entity 'thrombocytopenia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software